Timing is everything: new trial tests surgery before or after immunotherapy for kidney cancer

NCT ID NCT07233668

Not yet recruiting Disease control Sponsor: Seoul National University Hospital Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This clinical trial is for adults with metastatic clear cell kidney cancer. It compares having surgery to remove the kidney tumor either before or after starting immunotherapy drugs (ipilimumab and nivolumab). The goal is to see which timing helps people live longer without the cancer growing. 172 participants will be randomly assigned to one of the two groups and followed for 15 months.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Ipilimumab and Nivolumab (immunotherapy drugs)
What this could lead to: If successful, this trial could show the best timing for surgery combined with immunotherapy, potentially improving survival and quality of life for people with metastatic kidney cancer.
What could go wrong: This is a Phase 3 trial, but it's not yet recruiting and results are years away. The benefit of timing may be small, and both surgery and immunotherapy carry risks of serious side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CLEAR CELL RENAL CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

clear cell renal carcinoma renal cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC RENAL CELL CARCINOMA ( MRCC)

More trials for these conditions

Other studies related to the condition(s) this trial covers.